An expanded access record providing Nirogacestat (Gamma Secretase Inhibitor) in Desmoid Tumor and NOTCH Gene Mutation Positive Tumors, sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany. Available. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · Expanded access
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
Inclusion Criteria:
Patients will receive nirogacestat tablets to be taken orally.
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany